AVS Bio is the worlds largest producer of Specific Pathogen Free (SPF) eggs as well as laboratory products and services for the development and manufacture of Biologics.  We are establishing a research group to expand our new product offerings across both human and animal health markets.

Research Activities:

The research team is working on development of new products for the human and animal health markets.  One of our current projects is working on new IgY antibody products using SPF chicken eggs.

Alpha-1 Foundation is dedicated to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by Alpha-1 worldwide.

Research Activities:

We have invested more than $97 million into Alpha-1 research and related programs. Some twenty biotechs have drug development programs in progress of which one half are in clinical trial. About six are gene based interventions.

The National Organization for Rare Disorders (NORD) is a 501(c)(3) patient advocacy organization that improves the health and well-being of patients living with rare diseases by improving care, accelerating research, and driving public policy. Our Corporate Council comprises over a hundred biopharmaceutical companies, clinical research organizations, and other stakeholders involved in the drug development process for orphan treatments. NORD’s membership includes more than 340 patient advocacy organizations and 40+ Rare Disease Centers of Excellence, including Yale New Haven Hospital.

NORD’s headquarters are in Danbury, CT, and satellite offices are in Quincy, Massachusetts, and Washington, D.C.

Research Activities:

NORD is a leader in patient-focused drug development (PFDD) on behalf of the rare disease community. Through our medical affairs and research teams, and in partnership with patient advocacy groups and regulatory bodies, we are accelerating research for rare diseases through the following mechanisms:

– NORD brings together teams of clinical experts in a nationwide network of cutting-edge facilities, with the goal to provide standards of specialized care and disease management for people living with rare disease and their families

– Our IAMRARE® program helps researchers to develop and conduct natural history studies and patient registries on our platform that is designed to collect disease-specific and disease-agnostic patient experience data in multiple languages.

– We provide seed grants for academic scientists to pursue studies related to the development of potential new diagnostics or treatments in order to provide preliminary data and attract funding from government or industry sponsors.

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through the development of novel pharmaceutical therapies; and technologies that expand the availability of transplantable organs. You can learn more about what it means to be a PBC here.

Talam Biotech is leading the development of solutions that enable farmers to produce healthier, more sustainable food. At Talam, we leverage the power of naturally occurring soil microbes to reduce food-associated contaminants and remediate pollutants.

Research Activities:

Scientists at Talam specialize in microbiology, plant science and agronomy. Research activities include microbe discovery and characterization, product development, formulation, and both lab and field-based plant testing.

No one should face Alzheimer’s alone. The Connecticut Chapter of the Alzheimer’s Association offers programs and services, resources and support via phone, zoom and in person. Call us on our 24/7 Helpline at 800.272.3900 or visit alz.org/CT.

Schedule a meeting with a local Care Consultant to gain a better understanding of dementia, identify available resources, and develop personalized strategies. Support groups for caregivers or those with memory loss offer an opportunity to meet with others for supportive, meaningful discussion led by a trained facilitator. Our Early Stage Engagement program offers a fun and comfortable way to connect with others through art, music, culture, and more. Our education classes help you understand and meet the challenges related to Alzheimer’s or other dementia. 10 Warning Signs, Effective Communication, Managing Money programs and more are available. Our Advocacy volunteers make a difference on the state and national level by sharing their stories with lawmakers. Our Walk to End Alzheimer’s, The Longest Day, Celebrating Hope Gala and other fundraisers ensure we can offer care and support as well as move research forward.

The Alzheimer’s Association is the largest non-profit funder of research in the world, presently funding more than 1.9M in research right here in Connecticut at Yale and UConn Health. Local studies include looking at alcohol misuse and dementia risk, investigating the connection between depression and dementia and looking to improve the caregiver experience with resources after they take their loved one to the ER. Clinical Trials are for those who are healthy and those who are not, including caregivers, children of those with dementia and those with no memory issues. To find out more, check out our clinical matching service alz.org/trialmatch. Not only are there new treatments available that can change the course of the disease, there is a good deal of new information about lifestyle interventions to reduce your risk of Alzheimer’s. Incorporating exercise, the MIND or Mediterranean diet, social and cognitive stimulation and more health and wellness checks are healthy habits to adopt. We share the very latest in local and national research advancements to groups and businesses across the state, to make sure everyone is aware of our focus  on our mission: getting to a world without Alzheimer’s and other dementias.

Vision Search Partners conducts financial searches for life sciences companies throughout the northeast. Our team, which includes a former life sciences CFO with 26 years of industry experience, ensures we understand the unique knowledge and expertise requirements of each position, substantially reducing our clients’ hiring risk. Further, our deep roots and strong professional networks in the marketplace enable us to source candidates in a timely manner. We conduct searches for financial resources on a permanent and interim basis.

At Adventus Consulting, we help rapidly growing life science companies harness supplier value by developing procurement & sourcing processes supportive of growth, risk and cost management goals. Working with finance, legal, operational and procurement teams, we foster collaboration between company and supplier stakeholders to create an efficient corporate buying process across sourcing, contracting, and payment activities.

We believe the procurement function should support the business and not create an inefficient bureaucracy of confusing policies, processes and disconnected systems. We recognize each client’s situation and objectives to work with them to design and implement a procurement function to meet their business goals.

Corner Properties is a New Haven based, privately owned real estate investment company for real estate development and management. The company includes acquisition/development of biotech, flex, industrial, office, and mixed use properties. Noted for a high level of service to tenants, and identifying under-utilized assets, the company focuses on redevelopment and repositioning facilities to maximize their potential.

Whiting-Turner provides construction management, general contracting, design-build and integrated project delivery services on projects small and large for a diverse group of customers. Successful markets include office and headquarters, healthcare, senior living, science + technology, microelectronics, mission critical, retail, higher education, K-12, industrial, warehouse and distribution, transportation, multi-family residential, mixed-use, urban redevelopment, hospitality, entertainment, cultural, religious and public sector.

Since 1909, the firm has been guided by the principles of integrity, excellence and an unwavering dedication to customer delight. With headquarters in Baltimore and 60 locations across the country, Whiting-Turner is currently ranked third in domestic building construction by Engineering News-Record. The firm’s over 4,600 salaried professionals provide depth of resources to service nationally and to build locally.

The strength and stability of the firm is well documented. Whiting-Turner enjoys a 5A-1 Dun & Bradstreet rating – the only domestic builder with this highest rating – and a bonding capacity of $4 billion. The firm is financially independent, having not borrowed money since 1938.

For details on Whiting-Turner’s expertise building science and technology facilities, click here.